Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus

INTRODUCTION: Type 2 diabetes is increasing in prevalence worldwide and is a leading cause of morbidity and mortality, mainly due to the development of complications. Vildagliptin is an inhibitor of dipeptidyl peptidase 4 (DPP-4), a new class of oral antidiabetic agents. AIMS: To evaluate the role o...

Descripción completa

Detalles Bibliográficos
Autores principales: Profit, Louise, Chrisp, Paul, Nadin, Carole
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Place in Therapy Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899806/
https://www.ncbi.nlm.nih.gov/pubmed/20694081
http://dx.doi.org/10.3355/ce.2008.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899806/
https://www.ncbi.nlm.nih.gov/pubmed/20694081
http://dx.doi.org/10.3355/ce.2008.009

Ejemplares similares